RETA — Reata Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge Cap
- $6.52bn
- $6.27bn
- $2.22m
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer
U.S. STOCKS ON THE MOVE-Tupperware Brands, Comcast, Centene
U.S. STOCKS ON THE MOVE-Reata, Boston Beer, First Solar
Biogen slips on deal to acquire Reata Pharmaceuticals
Brief: Biogen To Acquire Reata Pharmaceuticals
Reata jumps on Biogen's $6.5 bln buyout to expand rare disease portfolio
Biogen to buy Reata for about $6.5 bln (updated)
Biogen considering takeover of biotech Reata - Bloomberg Law
Brief: Biogen Is Said To Weigh Takeover Of $4 Billion Drugmaker Reata- Bloomberg News
U.S. STOCKS ON THE MOVE-Cognition Therapeutics, Pinterest, Minerva Neurosciences
U.S. STOCKS ON THE MOVE-Overstock.com, Reata Pharma, Boeing
Reata Pharma up as rare disease drug becomes commercially available
Brief: Reata Pharmaceuticals Announces Approval Of Prior Approval Supplement For Skyclarys® (Omaveloxolone) And Commercial Availability Of Skyclarys For Patients With Friedreich's Ataxia
Brief: Adage Capital Partners GP L.L.C. Reports 5.24% Passive Stake In Reata Pharmaceuticals Inc As Of June 16 - SEC Filing
Reata Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Reata Pharmaceuticals Inc Reports Q1 2023 Financial Results, Provides Update On Operational Progress And Clinical Development Programs